Abstract
Polymorphisms in the drug transporter gene ABCB1 account for differences in the clinically efficacy of the most drugs, most likely by influencing their access to the brain. The majority proportion of depressed patients, given a regular dose, do not respond properly or experience severe side effects. One explanation may be the polymorphisms in the drug transporter gene ABCB1, which account for differences in the clinical efficacy of antidepressants, neuroleptics or mood stabilizers most likely by influencing their access to the brain. If patients are treated with a substrate of P-gp, functionally relevant genetic variants in the ABCB1 transporter could influence intracerebral drug concentrations and, thereby, clinical response. The review shows recently investigated clinical impact of ABCB1 variants including the three most important SNPs rs1045642, rs2032582, and rs2032583. In the paper, with respect not to go beyond the scope of this review, we will focus on these three SNPs. The final goal of pharmacogenetics is to help clinicians to choose the best treatment for each individual patient. From the evidence reviewed in this publication, it is likely that combination of metabolizing and drug target polymorphisms will produce the best prediction for the selection of the optimal dose and optimal drug as a function of the individual s genetic profile.
Keywords: ABCB1 transporter, P-glycoprotein, single nucleotide polymorphism, pharmacogenetic, amitriptyline, nortriptyline, antipsychotics, sulpiride, antidepressants, antiepileptics
Current Pharmaceutical Design
Title: The Clinical Impact of ABCB1 Polymorphisms on the Treatment of Psychiatric Diseases
Volume: 17 Issue: 26
Author(s): Marcus C. Rosenhagen and Manfred Uhr
Affiliation:
Keywords: ABCB1 transporter, P-glycoprotein, single nucleotide polymorphism, pharmacogenetic, amitriptyline, nortriptyline, antipsychotics, sulpiride, antidepressants, antiepileptics
Abstract: Polymorphisms in the drug transporter gene ABCB1 account for differences in the clinically efficacy of the most drugs, most likely by influencing their access to the brain. The majority proportion of depressed patients, given a regular dose, do not respond properly or experience severe side effects. One explanation may be the polymorphisms in the drug transporter gene ABCB1, which account for differences in the clinical efficacy of antidepressants, neuroleptics or mood stabilizers most likely by influencing their access to the brain. If patients are treated with a substrate of P-gp, functionally relevant genetic variants in the ABCB1 transporter could influence intracerebral drug concentrations and, thereby, clinical response. The review shows recently investigated clinical impact of ABCB1 variants including the three most important SNPs rs1045642, rs2032582, and rs2032583. In the paper, with respect not to go beyond the scope of this review, we will focus on these three SNPs. The final goal of pharmacogenetics is to help clinicians to choose the best treatment for each individual patient. From the evidence reviewed in this publication, it is likely that combination of metabolizing and drug target polymorphisms will produce the best prediction for the selection of the optimal dose and optimal drug as a function of the individual s genetic profile.
Export Options
About this article
Cite this article as:
C. Rosenhagen Marcus and Uhr Manfred, The Clinical Impact of ABCB1 Polymorphisms on the Treatment of Psychiatric Diseases, Current Pharmaceutical Design 2011; 17 (26) . https://dx.doi.org/10.2174/138161211797440140
DOI https://dx.doi.org/10.2174/138161211797440140 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Omega-3 Fatty Acids and their Role in Central Nervous System - A Review
Current Medicinal Chemistry Synthesis of the Neurotransmitter 4-Aminobutanoic Acid (GABA) from Diethyl Cyanomalonate
Letters in Drug Design & Discovery Microtubules (tau) as an Emerging Therapeutic Target: NAP (Davunetide)
Current Pharmaceutical Design Clinical Strategies for the Blockade of IL-18 in Inflammatory Bowel Diseases
Current Drug Targets Preparation and Characterization of Rivastigmine Loaded Human Serum Albumin (HSA) Nanoparticles
Current Drug Delivery Information of ADME-Associated Proteins and Potential Application for Pharmacogenetic Prediction of Drug Responses
Current Pharmacogenomics The Molecular Targets of Cannabinoids in the Treatment of Cancer and Inflammation
Current Pharmaceutical Design Editorial [Vigabatrin: An Antiepileptic Drug with Major Benefits but Significant Adverse Effects]
Current Drug Safety TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets Combined Therapies for Lysosomal Storage Diseases
Current Molecular Medicine Nuezhenide Exerts Anti-Inflammatory Activity through the NF-κB Pathway
Current Molecular Pharmacology Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases
Current Topics in Medicinal Chemistry Editorial (Adverse Effects, Adverse Events and Side-Effects: Does the Terminology Matter?
Current Drug Safety From Discovery to Clinical Trials: Treatment Strategies for Central Neuropathic Pain after Spinal Cord Injury
Current Pharmaceutical Design QSAR Studies on some Calcium Channel Blockers
Letters in Drug Design & Discovery Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Neurocognitive Functioning and Cannabis Use in Schizophrenia
Current Pharmaceutical Design Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Synthesis and Biological Evaluation of Novel 2,3-disubstituted Benzofuran Analogues of GABA as Neurotropic Agents
Medicinal Chemistry